By Peter Meath
The challenges created by the global COVID-19 pandemic have cast a spotlight on the life sciences industry and the lifesaving solutions that it can provide. We’re seeing an acceleration of interest in the space and a significant increase in resources, investments, and alternative sources of capital.
In the first half of 2020, life sciences companies secured 44 supergiant funding rounds of $100 million or more — a record number. During the year, investors globally put $16.55 billion to work across 450 deals in the biotech and life sciences sectors at Series A and beyond. That’s up considerably from 2019, when investors put $13.4 billion to work across nearly 600 known funding rounds.